strong>Bellerophon Therapeutics LLC, of Hampton, N.J., completed enrollment of its PRESERVATION I trial of Bioabsorbable Cardiac Matrix (BCM), an implantable medical device studied to prevent congestive heart failure following an acute myocardial infarction. The treatment procedure has been completed in 303 patients at almost 90 sites in Australia, Europe, Israel and North America.